Importance Non–small cell lung cancer remains the leading cause of cancer death in the
United States. Until the last decade, the 5-year overall survival rate for patients with …

Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for
patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). Understanding …

Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI),
potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance …

Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations …

Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus
gefitinib in treatment-naıve patients with advanced non–small-cell lung cancer (NSCLC) and …

Purpose: Patterns of resistance to first-line osimertinib are not well-established and have
primarily been evaluated using plasma assays, which cannot detect histologic …

Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …

Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …

Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing (EGFR m) and T790M …